Researchers at Lund University have unexpectedly discovered that an old cancer drug can be used to prevent rejection of transplanted tissue.
The researchers now have high hopes that their discovery could lead to new treatments for both transplant patients and patients with autoimmune diseases.
The researchers behind the study, which has been published in the scientific journal PLOS ONE, work at the Rausing Laboratory, Lund University, where they have conducted research on brain tumours over many years.
“Our group were studying the effects of the old tumour drug Zebularine, developed in the USA in the 1960s, and by chance we discovered that it had completely unexpected effects on the immune system”, says Leif Salford, Senior Professor of Neurosurgery.
“It turned out that Zebularine has the ability to subdue the reaction of the body’s immune system. This could be important in situations where tissue or organs are transplanted. We also think it could be used to curb the body’s attacks on its own tissue in autoimmune diseases, for instance type 1 diabetes or rheumatoid arthritis”, says Dr Nittby.
In studies on animals, the researchers used rats that were made diabetic. The researchers transplanted the islets of Langerhans – cell groups in the pancreas producing insulin – from healthy rats from another kind of rat into those with diabetes. The diabetic rats were divided into two groups; one group were treated with Zebularine and the other, the control group, did not receive any treatment. The diabetic rats that were treated with Zebularine survived for a significantly longer period than the untreated rats.
“It is very interesting that we only treated them with Zebularine for two weeks, but the effects of the treatment could be observed throughout the 90-day follow-up period.
“The findings are very exciting and are a sign that the immune system was not just generally suppressed, but that the treatment was more targeted. Neither did we see any signs of side-effects”, said Dr Nittby.
The researchers are now working intensively to further refine the treatment. The next step is to teach certain cells in the immune system – the dendritic cells – to accept certain specific proteins using the Zebularine treatment.
This would mean that the treatment could be targeted even more.
“If we succeed with that, we believe it could be of clinical significance both to prevent rejection of transplanted organs and to stop the body attacking its own tissue in autoimmune diseases.
The Latest Bing News on:
Zebularine
- Epigenetics of Estrogen Receptor-Negative Primary Breast Canceron May 4, 2024 at 5:00 pm
Expert Rev Mol Diagn. 2012;12(4):371-382. Table 1. Epigenetic elements that regulate ERα expression in breast cancer. Epigenetic element Molecular expression in ER-negative breast cancer Effect ...
- Barrett's Esophagus: Can Biomarkers Predict Progression to Malignancy?on April 5, 2024 at 5:00 pm
It was demonstrated, in vitro and in vivo, that re-expression of epigenetically silenced tumor-suppressor genes is possible by using demethylating (e.g., 5´-AZA and Zebularine) and histone ...
- Mechanism of action of nucleoside analogue inhibitors.on September 9, 2020 at 3:43 pm
Ribonucleosides such as 5-azacytidine or zebularine are reduced at the diphosphate level by ribonucleotide reductase for incorporation (not shown). Once in DNA, the fraudulent bases form covalent ...
The Latest Google Headlines on:
Zebularine
[google_news title=”” keyword=”Zebularine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Preventing rejection of transplanted tissue
- 'World first' for double hand transplant patienton May 9, 2024 at 12:30 pm
A woman who had a double hand transplant has undergone pioneering NHS treatment to prevent her body rejecting them. Tanya Shepherd, from Hull, became the UK’s first female recipient of two replacement ...
- Hull mum who was UK’s first female double hand transplant patient now receives ‘world first’ treatment to prevent rejectionon May 9, 2024 at 3:25 am
A Hull mum who became the UK’s first female recipient of a double hand transplant has undergone treatment, believed to be a world first, to prevent rejection of the body parts. Tanya Shepherd, 48, ...
- Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejectionon May 7, 2024 at 12:05 am
First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Company reports ...
- First Ever Combined Heart Pump and Pig Kidney Transplanton April 29, 2024 at 2:29 pm
A terminally sick patient has become the first person in history to receive a kidney transplant from a gene-edited pig ...
- Woman becomes 1st patient to undergo combined heart pump implant and pig kidney transplanton April 24, 2024 at 6:01 am
with the transplant of a genetically modified pig kidney and the pig's thymus gland -- which makes white blood cells to help the immune system fight disease -- to help prevent rejection.
- Woman becomes 1st patient to undergo combined heart pump implant and pig kidney transplanton April 23, 2024 at 11:01 pm
MORE: 2 patients receive double-lung transplants due to rare 'flipped organs' condition Additionally, Pisano has high levels of antibodies harmful to human tissue that would make it difficult to ...
- Woman is 1st patient to undergo combined heart pump implant and pig kidney transplanton April 23, 2024 at 5:00 pm
Additionally, Pisano has high levels of antibodies harmful to human tissue that would make it difficult to find a match for a human kidney transplant ... gal helps prevent rejection of ...
- MIT Technology Reviewon April 23, 2024 at 5:00 pm
That’s a concern even with human kidney transplants, but it’s an even greater risk when the tissue comes from another species, a procedure known as xenotransplantation. To prevent rejection ...
- Study finds promising biomarker for cellular rejection after organ transplanton April 17, 2024 at 5:00 pm
T cells are responsible for the most common kind of rejection, which clinicians call acute cellular rejection, or ACR. To prevent this ... injury to the transplanted tissue," says Vallabhajosyula.
- Researchers probe immune microenvironment to prevent pediatric liver transplant rejectionon April 16, 2024 at 5:01 pm
They used tissue biopsies from 79 adult liver transplant patients—including patients who received transplants at CHLA before age 18—who had either no rejection, acute T–cell-mediated ...
The Latest Google Headlines on:
Preventing rejection of transplanted tissue
[google_news title=”” keyword=”preventing rejection of transplanted tissue” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]